SCNI Scinai Immunotherapeutics: יחס מחיר להכנסות חזויות

Scinai Immunotherapeutics (SCNI) develops nanobodies to combat psoriasis and skin infections, ensuring high margins through patents. Therapy safety is guaranteed by strict adherence to the cold chain during component transportation. The company's forward P/S visualizes price volatility during market shocks, with the current value standing at 0.20. Demand for inhalable drug formulations is currently at the pre-commercial stage.
Scinai Immunotherapeutics - פילוחים אנליטיים ומדדי מפתח (SCNI)

For the biotechnology sector of Scinai Immunotherapeutics (SCNI), where revenue depends on grants and nanobody clinical trials, the organization's forward P/S serves as a gauge of market expectations regarding future sales. The ratio of market capitalization to expected revenue for the following year allows for an assessment of the asset's overbought status, determining the margin of safety for investments in the absence of stable cash flows.